0001209191-15-084255.txt : 20151209
0001209191-15-084255.hdr.sgml : 20151209
20151209163106
ACCESSION NUMBER: 0001209191-15-084255
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151207
FILED AS OF DATE: 20151209
DATE AS OF CHANGE: 20151209
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levy Richard S
CENTRAL INDEX KEY: 0001454983
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 151278664
MAIL ADDRESS:
STREET 1: EXPERIMENTAL STATION
STREET 2: ROUTE 141 AND HENRY CLAY RD
CITY: WILMINGTON
STATE: DE
ZIP: 19880
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-12-07
0
0000879169
INCYTE CORP
INCY
0001454983
Levy Richard S
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
EVP, Chief Drug Dev Officer
Common Stock
2015-12-07
4
M
0
3937
18.32
A
20863
D
Common Stock
2015-12-07
4
S
0
3937
106.18
D
16926
D
Non-Qualified Stock Option (right to buy)
18.32
2015-12-07
4
M
0
3937
0.00
D
2020-02-08
Common Stock
3937
6813
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
Represents weighted average sale price. Actual sale prices ranged from $105.22 - $109.03.
Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.
/s/ Richard S. Levy
2015-12-09